LataMed AI Corp. (OTC: LMED) provided shareholders with an update on the implementation of its previously announced 5-for-1 forward stock split and related mandatory share exchange process. As of July 7, 2026, the Company has submitted all required information to FINRA and anticipates the corporate action may become effective within approximately the next week, subject to FINRA's review and final processing.
The forward stock split will be implemented alongside the assignment of a new CUSIP number, 21116R404, to facilitate the mandatory share exchange. Management emphasized that the split supports the Company's corporate development and strategic initiatives, including the advancement of its telemedicine platform and AI technologies.
Shareholders holding shares through brokerage accounts are generally not required to take any action, as the exchange will be processed automatically. Similarly, registered book-entry shareholders with the transfer agent will have their accounts updated automatically. However, physical stock certificate holders are not required to immediately surrender their certificates; when they later submit them for transfer, sale, or exchange, the transfer agent will issue post-split shares under the new CUSIP.
CEO Dr. Kevin Rodan Levy stated, "We want to ensure that our shareholders clearly understand how the forward stock split and mandatory exchange process will be implemented." He added that management intends to focus on advancing the Company's telemedicine platform and pursuing licensing opportunities for CardioAI, PulmoAI, and NeuroAI platforms, which are central to building an integrated digital healthcare ecosystem in Latin America.
Additional details regarding exchange procedures will be provided by the Company's transfer agent. Shareholders with questions should contact their brokerage firm or the transfer agent once instructions are available. The Company will provide further updates once FINRA establishes the official effective date.
For more information, visit https://latamed.ai or review filings with the SEC at www.sec.gov.
